Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Details

Files
Generic Name:
Osimertinib
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer (NSCLC) (first line)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Tagrisso
Project Line:
Reimbursement Review
Project Number:
PC0137-000
NOC Status at Filing:
Pre NOC
Strength:
40 mg and 80 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (first line)
Funding Request:
For the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations
Pre Noc Submission:
Yes
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.